Here are the 10-K annual reports from QT Imaging Holdings, Inc. (QTI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow QTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QTI filings page.
QT Imaging Holdings, Inc. files its annual report describing a breast imaging business built around its QT Breast Scanner, a 3D ultrasound tomography system that avoids ionizing radiation and breast compression. The device received initial FDA 510(k) clearance in June 2017, an additional quantitative breast density clearance in August 2022, and a further clearance on March 10, 2026 for an enhanced configuration that improves imaging of posterior breast tissue near the chest wall.
The company outlines a strategy to evolve from a hardware maker into a precision imaging platform by adding a cloud SaaS infrastructure and future AI modules for quantitative biomarkers and diagnostic decision support. It targets the breast imaging market, which the report cites at about $6.04 billion globally in 2025, and references broader medical imaging and cancer screening markets. Commercially, QT Imaging has an exclusive U.S. distribution agreement with NXC Imaging, tied to minimum order quantities, and exclusive distribution deals with Gulf Medical Co. in Saudi Arabia and Al Naghi Medical Co. in the UAE. The Al Naghi agreement includes minimum orders totaling 43 scanners from 2026 through 2028, representing more than $24 million in revenue commitments, subject to performance and supply conditions.